Clinical oncologists face many challenges to identify the best use of the anti-EGFR drugs in patients with non-small-cell-lung cancer. Thanks to genetic analysis, they are now able to identify responders from non-responders and to counteract [more]
Skin rash and itchy skin are known to be common side-effects in patients treated with EGFR and tyrosine kinase inhibitors, and can be distressing, particularly when severe. A growing understanding of why this happens is [more]
Targeted drugs can result in a variety of skin toxicities that are unpleasant for patients and, if unattended to, can lead them to stop taking their drug as prescribed. Effective teamwork is required to ensure [more]
Selected reports edited by Hannah Brown Download full article
EGFR inhibitors represent a bright hope for modern cancer therapies. But treatment comes at a price an acne-like rash and other skin problems that can blight people’s lives. As these drugs become used more [more]